Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MYGN

Myriad Genetics, Inc.

May 10 • 04:00PM ET

25.47

Dollar change +0.22
Percentage change 0.87	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IJR VTI IWM VB VBR VXF IWN IBB IJS IJT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.82	Insider Own	4.29%	Shs Outstand	89.90M	Perf Week	30.82%
Market Cap	2.31B	Forward P/E	117.10	EPS next Y	0.22	Insider Trans	-0.77%	Shs Float	86.62M	Perf Month	24.24%
Income	-234.60M	PEG	-	EPS next Q	-0.01	Inst Own	102.19%	Short Float	6.87%	Perf Quarter	15.77%
Sales	774.20M	P/S	2.98	EPS this Y	111.11%	Inst Trans	1.69%	Short Ratio	8.54	Perf Half Y	42.37%
Book/sh	8.40	P/B	3.03	EPS next Y	625.00%	ROA	-20.58%	Short Interest	5.95M	Perf Year	43.33%
Cash/sh	1.15	P/C	22.10	EPS next 5Y	-8.20%	ROE	-29.41%	52W Range	13.82 - 25.28	Perf YTD	33.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-26.27%	52W High	0.75%	Beta	1.97
Dividend TTM	-	Quick Ratio	1.82	Sales past 5Y	4.63%	Gross Margin	63.25%	52W Low	84.30%	ATR (14)	1.11
Dividend Ex-Date	-	Current Ratio	1.99	EPS Y/Y TTM	-56.54%	Oper. Margin	-15.82%	RSI (14)	78.65	Volatility	5.61% 4.33%
Employees	2700	Debt/Eq	0.19	Sales Y/Y TTM	11.44%	Profit Margin	-30.30%	Recom	2.69	Target Price	24.17
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	57.02%	Payout	-	Rel Volume	1.63	Prev Close	25.25
Sales Surprise	4.49%	EPS Surprise	90.40%	Sales Q/Q	11.59%	Earnings	May 07 AMC	Avg Volume	696.75K	Price	25.47
SMA20	30.07%	SMA50	22.94%	SMA200	33.55%	Trades		Volume	1,134,706	Change	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform	$25 → $35
Dec-21-23	Resumed	Piper Sandler	Neutral	$23
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$20
Dec-14-23	Initiated	Guggenheim	Buy	$23
Dec-13-23	Initiated	Wolfe Research	Outperform	$28
Jul-05-23	Resumed	JP Morgan	Underweight	$18
May-23-23	Upgrade	Goldman	Sell → Buy	$18 → $25
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$25
Oct-06-22	Initiated	Stephens	Equal-Weight	$22
Oct-15-21	Resumed	Cowen	Market Perform	$33
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Sell	$25
Sep-26-19	Downgrade	BofA/Merrill	Neutral → Underperform	$30 → $28
Aug-14-19	Downgrade	Piper Jaffray	Overweight → Neutral	$45 → $40
Aug-02-19	Upgrade	BofA/Merrill	Underperform → Neutral
Aug-01-19	Upgrade	Barclays	Underweight → Equal Weight	$18 → $40
Jul-29-19	Downgrade	Needham	Strong Buy → Hold
Jul-09-19	Downgrade	Cowen	Outperform → Market Perform
Mar-12-19	Reiterated	Needham	Strong Buy	$37 → $41
Jan-03-19	Initiated	Needham	Strong Buy	$36

Show Previous Ratings

May-10-24 06:00AM	Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life (InvestorPlace)
May-09-24 06:55PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) +5.43%
May-08-24 04:28PM	Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Call Transcript (Insider Monkey) +21.08%
03:59PM	Sector Update: Health Care Stocks Softer Late Afternoon (MT Newswires)
01:54PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
01:24PM	Loading…
01:24PM	Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue (MT Newswires)
12:15PM	Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1 (Zacks)
03:47AM	Myriad Genetics Inc (MYGN) Q1 2024 Earnings Call Transcript Highlights: Strong Start with ... (GuruFocus.com)
May-07-24 09:56PM	MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00PM	Myriad (MYGN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
06:02PM	Myriad Genetics Reports Q1 2024 Earnings: Revenue Growth Surpasses Estimates Amidst Challenges (GuruFocus.com)
05:50PM	Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:47PM	Myriad: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA (GlobeNewswire)
09:00AM	Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business (GlobeNewswire)
04:05PM	Loading…
Apr-30-24 04:05PM	Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-24-24 10:01AM	Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-17-24 08:00AM	Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor (GlobeNewswire)
Apr-16-24 09:15AM	New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen (GlobeNewswire)
Apr-11-24 10:00AM	Myriad Genetics (MYGN) Announces Favorable Research Results (Zacks)
Apr-09-24 09:10AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
08:00AM	Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing (GlobeNewswire)
Mar-28-24 11:30AM	Why Is Myriad (MYGN) Down 1% Since Last Earnings Report? (Zacks)
Mar-27-24 07:51AM	Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay (Zacks)
Mar-21-24 09:40PM	Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date (GlobeNewswire)
Mar-20-24 04:05PM	Myriad Genetics Announces Patent Granted for SneakPeek Snap Device (GlobeNewswire)
Mar-01-24 09:41AM	Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact (Zacks) +5.97%
Feb-28-24 02:45PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) -8.04%
11:24AM	Q4 2023 Myriad Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
10:24AM	Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:50AM	Loading…
07:50AM	Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down (Zacks)
Feb-27-24 07:00PM	Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:30PM	Myriad Genetics (MYGN) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:42PM	Myriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023 (GuruFocus.com)
04:05PM	Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance (GlobeNewswire)
09:15AM	Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 (GlobeNewswire)
Feb-26-24 09:16AM	Wall Street's Insights Into Key Metrics Ahead of Myriad (MYGN) Q4 Earnings (Zacks)
Feb-21-24 04:05PM	Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (GlobeNewswire)
Feb-16-24 07:05AM	Larry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics Inc (GuruFocus.com)
Feb-15-24 04:05PM	Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's Health (GlobeNewswire)
Feb-01-24 09:25AM	Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics (GlobeNewswire)
Jan-30-24 05:00PM	Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology (GlobeNewswire)
Jan-25-24 07:05PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Jan-22-24 08:55AM	Myriad's (MYGN) New Acquisition to Boost Precision Oncology Arm (Zacks) +5.17%
Jan-18-24 06:10PM	Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics (GlobeNewswire)
Jan-09-24 04:05PM	Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO (GlobeNewswire)
Jan-04-24 11:10AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
Jan-03-24 04:05PM	Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 03:05PM	Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation (Benzinga)
09:17AM	Myriad Genetics' (MYGN) New Platform to Advance Cancer Care (Zacks)
08:30AM	Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance (GlobeNewswire)
Dec-20-23 08:00AM	Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care (GlobeNewswire)
Dec-14-23 08:22AM	Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes (Zacks)
Dec-06-23 11:30AM	Why Is Myriad (MYGN) Up 3% Since Last Earnings Report? (Zacks)
Nov-21-23 10:54AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
Nov-20-23 04:05PM	Myriad Genetics Celebrates One Million SneakPeek Results Shared with Expectant Parents (GlobeNewswire)
11:18AM	Myriad Genetics (MYGN) Expands Pharma Services With New Pact (Zacks)
Nov-16-23 04:05PM	Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers (GlobeNewswire)
Nov-09-23 07:00AM	Myriad Genetics to Participate in Stephens Annual Investment Conference (GlobeNewswire) -8.94%
Nov-08-23 09:20PM	Myriad Genetics Announces Pricing of Upsized Offering of Common Stock (GlobeNewswire)
04:10PM	Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock (GlobeNewswire)
Nov-07-23 02:30PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) +8.69%
10:24AM	Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:09AM	Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3 (Zacks)
Nov-06-23 07:00PM	Myriad (MYGN) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
04:59PM	Myriad Genetics Inc (MYGN) Reports 23% YoY Revenue Growth in Q3 2023 (GuruFocus.com)
04:36PM	Myriad: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance (GlobeNewswire)
Nov-04-23 03:02AM	Insider Sell: CFO Richard Riggsbee Sells 30,000 Shares of Myriad Genetics Inc (GuruFocus.com)
Nov-03-23 07:04PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) +6.51%
Nov-01-23 09:00AM	Myriad Genetics Appoints Sam Raha as Chief Operating Officer (GlobeNewswire)
Oct-31-23 04:05PM	Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023 (GlobeNewswire) +7.60%
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-26-23 08:00AM	QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer (GlobeNewswire)
Oct-20-23 10:31AM	Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research (PR Newswire)
Oct-09-23 06:56PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Sep-29-23 11:44AM	Is Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
Sep-28-23 04:59PM	BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD (PR Newswire)
07:00AM	New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood (GlobeNewswire)
Sep-22-23 11:51AM	Is Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
Sep-20-23 07:42AM	Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up (Zacks)
Sep-19-23 09:00AM	Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials (GlobeNewswire)
07:00AM	Myriad Genetics Issues 2022 Environmental, Social and Governance Report (GlobeNewswire)
Sep-18-23 08:00AM	Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer (GlobeNewswire)
Sep-12-23 11:41AM	Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now (Zacks)
Sep-08-23 11:49AM	Is Myriad Genetics (MYGN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
Sep-07-23 11:30AM	Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report? (Zacks)
Sep-06-23 04:05PM	Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work (GlobeNewswire)
07:00AM	New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women (GlobeNewswire)
Sep-05-23 08:00AM	Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-23-23 09:48AM	Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk (Zacks)
Aug-22-23 09:00AM	Myriad Genetics and Onsite Womens Health Partner to Help More Women Understand Breast Cancer Risk (GlobeNewswire)
Aug-17-23 04:05PM	Myriad Genetics to Host Investor Day on September 19, 2023 (GlobeNewswire)
Aug-16-23 08:36AM	Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test (Zacks)
Aug-15-23 07:05AM	Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris® (GlobeNewswire)
Aug-11-23 10:34AM	Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement (Zacks) +7.19%
Aug-08-23 04:05PM	Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment (GlobeNewswire)
Aug-07-23 04:05PM	Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status (GlobeNewswire) -9.53%
12:12PM	Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss (Zacks)
Aug-05-23 08:29AM	Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2023 Earnings Call Transcript (Insider Monkey)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Riggsbee Richard Bryan	Chief Financial Officer	Dec 01 '23	Sale	19.09	30,000	572,835	291,812	Dec 05 04:19 PM
Riggsbee Richard Bryan	Chief Financial Officer	Nov 01 '23	Sale	15.69	30,000	470,622	321,812	Nov 03 05:12 PM
SPIEGELMAN DANIEL K	Director	Jun 02 '23	Sale	23.01	8,638	198,760	40,493	Jun 02 06:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MYGN

Myriad Genetics, Inc.

Upgrade your FINVIZ experience